View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Nagyerdei krt. 98., 4032
Open access

Absztrakt:

A progranulin egy újonnan felfedezett multifunkcionális glikoprotein, amely összefüggésben van az elhízás és a cukorbetegség kialakulásával. A progranulin a tumornekrózisfaktor-α endogén antagonistája, kompetitíven kötődik annak receptorához, így antiinflammatoricus aktivitással rendelkezik. Érdekes módon korábbi tanulmányok kimutatták, hogy a progranulin szérumszintje emelkedett a cukorbetegekben, és összefüggésbe hozták a cukorbetegség bizonyos komplikációival, beleértve a micro- és macroangiopathiát, a macroalbuminuriát és a csökkent vesefunkciót. Továbbá a hyperprogranulinaemia közrejátszhat az elhízáshoz társuló inzulinrezisztencia patogenezisében. A cikkben összefoglaljuk a jelenleg elérhető adatokat a progranulinnak – mint új markernek – a szénhidrát-metabolizmusban és a gyulladásban betöltött szerepére vonatkozóan. Orv Hetil. 2019; 160(25): 973–979.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Weisman A, Fazli GS, Johns A, et al. Evolving trends in the epidemiology, risk factors, and prevention of type 2 diabetes: a review. Can J Cardiol. 2018; 34: 552–564.

  • 2

    Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14: 88–98.

  • 3

    Kalofoutis C, Piperi C, Kalofoutis A, et al. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. Exp Clin Cardiol. 2007; 12: 17–28.

  • 4

    Veldman BA, Vervoort G. Pathogenesis of renal microvascular complications in diabetes mellitus. Neth J Med. 2002; 60: 390–396.

  • 5

    Khalil H. Diabetes microvascular complications – a clinical update. Diabetes Metab Syndr. 2017; 11(Suppl 1): S133–S139.

  • 6

    Nunemaker CS. Considerations for defining cytokine dose, duration, and milieu that are appropriate for modeling chronic low-grade inflammation in type 2 diabetes. J Diabetes Res. 2016; 2016: 2846570.

  • 7

    Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017; 10: 345–361.

  • 8

    Márk L, Harangi M, Paragh G. The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis. [A residualis kockázat útvesztői: a maradék lipid és gyulladásos kockázat csökkentése az atherosclerosis prevenciójában.] Orv Hetil. 2018; 159: 124–130. [Hungarian]

  • 9

    Babik B, Peták F, Agócs S, et al. Diabetes mellitus: endothelial dysfunction and changes in hemostasis. [Diabetes mellitus: endotheldiszfunkció és haemostasiselváltozások.] Orv Hetil. 2018; 159: 1335–1345. [Hungarian]

  • 10

    Bateman A, Bennett HP. Granulins: the structure and function of an emerging family of growth factors. J Endocrinol. 1998; 158: 145–151.

  • 11

    Plowman GD, Green JM, Neubauer MG, et al. The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. J Biol Chem. 1992; 267: 13073–13078.

  • 12

    Zhou J, Gao G, Crabb JW, et al. Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line. J Biol Chem. 1993; 268: 10863–10869.

  • 13

    Baba T, Hoff HB 3rd, Nemoto H, et al. Acrogranin, an acrosomal cysteine-rich glycoprotein, is the precursor of the growth-modulating peptides, granulins, and epithelins, and is expressed in somatic as well as male germ cells. Mol Reprod Dev. 1993; 34: 233–243.

  • 14

    Bhandari V, Palfree RG, Bateman A. Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci U S A 1992; 89: 1715–1719.

  • 15

    He Z, Bateman A. Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res. 1999; 59: 3222–3229.

  • 16

    Koo DH, Park CY, Lee ES, et al. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS ONE 2012; 7: e39880.

  • 17

    Han JJ, Yu M, Houston N, et al. Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol. 2011; 120: 5–10.

  • 18

    Demorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2013; 2: 145–151.

  • 19

    Donald CD, Laddu A, Chandham P, et al. Expression of progranulin and the epithelin/granulin precursor acrogranin correlates with neoplastic state in renal epithelium. Anticancer Res. 2001; 21: 3739–3742.

  • 20

    Hrabal R, Chen Z, James S, et al. The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol. 1996; 3: 747–752.

  • 21

    He Z, Ong CH, Halper J, et al. Progranulin is a mediator of the wound response. Nat Med. 2003; 9: 225–229.

  • 22

    Tolkatchev D, Ng A, Vranken W, et al. Design and solution structure of a well-folded stack of two β-hairpins based on the amino-terminal fragment of human granulin A. Biochemistry 2000; 39: 2878–2886.

  • 23

    Bhandari V, Bateman A. Structure and chromosomal location of the human granulin gene. Biochem Biophys Res Commun. 1992; 188: 57–63.

  • 24

    Bucan M, Gatalica B, Baba T, et al. Mapping of GRN, the gene encoding the granulin/epithelin precursor (acrogranin), to mouse Chromosome 11. Mamm Genome 1996; 7: 704–705.

  • 25

    Bhandari V, Giaid A, Bateman A. The complementary deoxyribonucleic acid sequence, tissue distribution, and cellular localization of the rat granulin precursor. Endocrinology 1993; 133: 2682–2689.

  • 26

    Daniel R, He Z, Carmichael KP, et al. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000; 48: 999–1009.

  • 27

    Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009; 132(Pt 3): 583–591.

  • 28

    Martens LH, Zhang J, Barmada SJ, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012; 122: 3955–3959.

  • 29

    Zheng Y, Brady OA, Meng PS, et al. C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. PLoS ONE 2011; 6: e21023.

  • 30

    Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111: 867–878.

  • 31

    Tang W, Lu Y, Tian QY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011; 332: 478–484.

  • 32

    Park B, Buti L, Lee S, et al. Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity 2011; 34: 505–513.

  • 33

    Nguyen AD, Nguyen TA, Cenik B, et al. Secreted progranulin is a homodimer and is not a component of high density lipoproteins (HDL). J Biol Chem. 2013; 288: 8627–8635.

  • 34

    Huang K, Chen A, Zhang X, et al. Progranulin is preferentially expressed in patients with psoriasis vulgaris and protects mice from psoriasis-like skin inflammation. Immunology 2015; 145: 279–287.

  • 35

    Yamamoto Y, Takemura M, Serrero G, et al. Increased serum GP88 (progranulin) concentrations in rheumatoid arthritis. Inflammation 2014; 37: 1806–1813.

  • 36

    Zhou M, Tang W, Fu Y, et al. Progranulin protects against renal ischemia/reperfusion injury in mice. Kidney Int. 2015; 87: 918–929.

  • 37

    Nicoletto BB, Canani LH. The role of progranulin in diabetes and kidney disease. Diabetol Metab Syndr. 2015; 7: 117.

  • 38

    Langenberg C, Sharp SJ, Schulze MB, et al. Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. PLoS Med. 2012; 9: e1001230.

  • 39

    Youn BS, Bang SI, Klöting N, et al. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes 2009; 58: 627–636.

  • 40

    Matsubara T, Mita A, Minami K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab. 2012; 15: 38–50.

  • 41

    Carecchio M, Fenoglio C, De Riz M, et al. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer’s disease. J Neurol Sci. 2009; 287: 291–293.

  • 42

    Shafaei A, Marjani A, Khoshnia M. Serum progranulin levels in type 2 diabetic patients with metabolic syndrome. Rom J Intern Med. 2016; 54: 211–216.

  • 43

    Faerch K, Vaag A, Witte DR, et al. Predictors of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and women – the Inter99 study. Diabet Med. 2009; 26: 377–383.

  • 44

    Qu H, Deng H, Hu Z. Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediators Inflamm. 2013; 2013: 360190.

  • 45

    Xu L, Zhou B, Li H, et al. Serum levels of progranulin are closely associated with microvascular complication in type 2 diabetes. Dis Markers 2015; 2015: 357279.

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu